ProCE Banner Activity

Phase III Trial of Blinatumomab vs Chemotherapy as Post-Reinduction Therapy for Children and Young Adults With Relapsed B-ALL

Slideset Download
Conference Coverage
In children and young adults with intermediate- and high-risk first relapse of B-ALL, blinatumomab improved outcomes vs chemotherapy when administered as post-reinduction consolidation therapy prior to transplant.

Released: December 20, 2019

Expiration: December 18, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company